<DOC>
	<DOCNO>NCT01323751</DOCNO>
	<brief_summary>Phase 1 ( &amp; b ) : To evaluate side effect determine best dose oral ACY-1215 monotherapy , also combination bortezomib dexamethasone patient relapse relapsed/refractory multiple myeloma . Phase 2a : To determine objective response rate oral ACY-1215 combination bortezomib dexamethasone patient relapse relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Study ACY-1215 Alone Combination With Bortezomib Dexamethasone Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient relapse relapsed/refractory MM measurable disease parameter accord International Myeloma Working Group ( IMWG ) Criteria Refractory define experience less minimal response ( MR ) progressive disease ( PD ) within 60 day completion recent antiMM regimen Relapsed defined experience PD require therapy refractory follow achievement stable disease ( SD ) well recent antiMM regimen . Patient receive least 2 prior regimen MM . Patient receive prior treatment MM proteasome inhibitor immunomodulatory drug , unless candidate proteasome inhibitor immunomodulatory drug . Patient either candidate autologous stem cell transplant ( ASCT ) , decline option ASCT , relapse prior ASCT . Patient ≥18 year age . Patient Karnofsky Performance Status score ≥70 Patient adequate bone marrow reserve , evidence : Absolute neutrophil count ( ANC ) ≥1.0x109/L . Platelet count ≥ 75x109/L patient &lt; 50 % bone marrow nucleate cell plasma cell ≥50x109/L patient 50 % bone marrow nucleate cell plasma cell . Patient adequate renal function ( calculated creatinine clearance ≥30 mL/min accord CockroftGault ) Patient adequate hepatic function ( serum bilirubin value &lt; 2.0 mg/dL ALT and/or AST value &lt; 3 × upper limit normal ULN ) . Patient correct serum calcium ≤ULN . Exclusion Criteria Patient receive follow therapy : Radiotherapy systemic therapy within 2 week baseline Prior peripheral autologous stem cell transplant within 12 wks Baseline . Prior allogeneic stem cell transplant . Prior treatment HDAC inhibitor . Patient active systemic infection require treatment . Patient history malignancy unless undergone definitive treatment 5 yr prior study without evidence recurrent malignant disease ( exclude basal cell carcinoma skin ; superficial carcinoma bladder ; carcinoma prostate current prostatespecific antigen &lt; 0.1 ng/mL ; cervical intraepithelial neoplasia ) . Patient know suspect HIV , positive hepatitis B know suspect active hepatitis C infection . Patient history significant cardiovascular , neurological , endocrine , gastrointestinal , respiratory , inflammatory illness include recent myocardial infarction ( within 6 month ) stroke ; hypertension require &gt; 2 medication adequate control ; diabetes mellitus &gt; 2 episode ketoacidosis precede 12 month ; chronic obstructive pulmonary disease ( COPD ) require &gt; 2 hospitalization precede 12 month . Patient QTcF value &gt; 480 msec ; family personal history long QTc syndrome ventricular arrhythmia include ventricular bigeminy ; previous history druginduced QTc prolongation Patient &gt; Grade 2 painful neuropathy peripheral neuropathy Patient history allergic reaction attributable bortezomib compound contain boron mannitol ( Phase 1b 2a )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>